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Every day about 1,150 people die – largely avoidably - due to asthma1. In comparison
malaria kills about 1,175 people per day.2 The great majority of asthma deaths occur in
children and adults living in the tropics, where effective asthma management may be either
non-existent or inaccessible. Yet with correct diagnosis and treatment many deaths from
asthma could be prevented.
The recent Lancet Commission3 suggested new ways of thinking about asthma, challenging
conventional concepts of asthma as a single disease and proposing a more targeted
approach. While development of novel phenotype-driven approaches occurs, robust
evidence shows that people with asthma symptoms improve with the World Health
Organisation’s (WHO) “essential asthma medicines”, and thus the term asthma as a clinical
diagnosis opens the door to asthma management.
Inhaled β2-agonists and inhaled corticosteroids are the cornerstone of effective management
for asthma. These classes of medicine were developed over half a century ago and their role
in cost-effective treatment and prevention of exacerbations and deaths, as well as control of
asthma symptoms is well established. However, most deaths and disability due to asthma
occur in people who are not taking medicines, especially inhaled corticosteroids, which are
more expensive. We therefore ask: “how much longer must children and adults with asthma
living in the tropics have to wait for these essential medicines?”
The Global Burden of Disease Study has estimated that there are 339 million people with
asthma globally, representing roughly 1 in 20 of the world’s population.4 Asthma is the
commonest chronic disease in children and remains one of the commonest chronic diseases
in adults. Limited access to appropriate management leads to mortality and morbidity
avoidable by straightforward strategies and actions.
These strategies and actions are described in the Global Asthma Report 2018,5 written by
53 authors from around the world and produced by the Global Asthma Network.6 The Report
sets out what is known about asthma, its burden, management and where the major gaps
lie, highlighting the above issues, intending to influence those in authority to act promptly
and wisely to reduce the global burden of asthma. The Global Asthma Report 2018 has 22
recommendations (five to WHO, nine to governments, four to health authorities and four to
health professionals, professional societies and patient organisations) mainly about the need
for better access to affordable quality-assured essential asthma medicines, better asthma
management packages, better asthma data, and more asthma research.
Infectious diseases such as malaria (“tropical diseases”) have been a scourge on humankind
forever but over the last century global death rates from tropical diseases have fallen due to
evidence-based public health measures. At the same time noncommunicable diseases
(NCDs) have risen. They now cause 71% of global deaths, 85% of which occur in low- and
middle-income countries (LMICs).7 Age-specific death rates are nearly double in LMICs
compared to high-income countries. In 2011, asthma was among four main groups of NCDs
prioritised by the United Nations (cardiovascular diseases, cancer, diabetes, chronic
respiratory diseases). These four account for about 80% of NCD deaths.7 Globally, asthma
is ranked 16th among the leading causes of years lived with disability4 and 25th for all ages
among the causes of burden of disease measured by disability adjusted life years.8
Remarkably, asthma management including essential asthma medicines was not included in
WHO’s 2011 “Scaling up actions against NCDs”9 and was not listed as a “Best Buy” or highly
cost-effective intervention in subsequent WHO publications like the Global Plan.10 In 2017,
using the WHO-CHOICE methodology, WHO reported that low dose inhaled beclometasone
and a short-acting β2-agonist was effective (not a “Best Buy”) and cost 1000-5000
international dollars per DALY averted in LMICs,11, 12. However, the basis for this high
estimate is not readily apparent in WHO’s Technical Papers, 12, 13 which cite evidence that
regular use of inhaled corticosteroids reduces the risk of death due to asthma by 87% (and,
incorrectly, attribute the same benefit to inhaled salbutamol therapy).12 The technical briefing
appears to assume that only 1.5% of people with asthma will use inhaled corticosteroids, a
grossly sub-optimal level of coverage, as the proportion should be at least 25% in children,
and higher in adults. To advance the care of asthma, better data and better models of cost-
effectiveness are needed.
There is abundant evidence that asthma can be controlled in resource-poor settings. For
example, in four asthma pilot projects (Benin, China, El Salvador and Sudan) funded by the
World Bank and organised by the International Union Against Tuberculosis and Lung
Disease and its partners, the training of clinicians in implementation of guidelines and
evaluation of outcomes was combined with the procurement of affordable, quality-assured,
essential asthma medicines,5 after one year all countries observed a substantial reduction in
asthma severity, visits to emergency services and hospitalisations. It would provide further
evidence if countries evaluated the costs and outcomes of their own asthma management
activities, to measure how the provision of affordable quality-assured essential asthma
medicines and more efficient, targeted and equitable delivery of standardised asthma care
reduces the burden of asthma on patients and health services.
The Global Asthma Report 2018,5 describes the steps required to reduce the burden and
mortality from asthma, and the data needed to monitor progress. The Global Asthma
Network Phase I will be completed in 2019.6 It will estimate the prevalence and severity of
asthma, describe risk factors and management in adults and children, and provide up-to-
date data, and time trends where previous comparable data exists.14
This patient story from Kenya 5 should be a thing of the past
“…I had run away from my husband, so that I go die in my parents’ home. I had to stop
working at the factory and I could not even do the housework….”
We call time on avoidable asthma deaths and on people with asthma not having the right to
quality of life.
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